METTL3 and colorectal cancer: In colorectal cancer, targeting METTL3 reprograms the TME by lowering pro-tumor chemokines (CXCL1, CXCL5, CCL20) and enhancing antitumor responses, consistent with a METTL3→chemokine axis that favors myeloid recruitment and immune evasion.